Thrivent Financial for Lutherans Purchases 49,678 Shares of Bristol-Myers Squibb (NYSE:BMY)

Thrivent Financial for Lutherans grew its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 42.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 166,479 shares of the biopharmaceutical company's stock after acquiring an additional 49,678 shares during the quarter. Thrivent Financial for Lutherans' holdings in Bristol-Myers Squibb were worth $9,450,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of BMY. Truist Financial Corp boosted its stake in Bristol-Myers Squibb by 3.9% during the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock worth $90,335,000 after buying an additional 60,365 shares in the last quarter. Contravisory Investment Management Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $488,000. Inspire Trust Co. N.A. increased its stake in Bristol-Myers Squibb by 39.0% in the third quarter. Inspire Trust Co. N.A. now owns 103,500 shares of the biopharmaceutical company's stock valued at $5,355,000 after acquiring an additional 29,044 shares during the period. iA Global Asset Management Inc. raised its position in Bristol-Myers Squibb by 81.3% in the third quarter. iA Global Asset Management Inc. now owns 76,775 shares of the biopharmaceutical company's stock worth $3,972,000 after purchasing an additional 34,418 shares in the last quarter. Finally, Bellevue Group AG bought a new position in Bristol-Myers Squibb during the third quarter worth about $1,905,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Trading Down 0.0 %

NYSE BMY traded down $0.02 during trading hours on Wednesday, hitting $59.18. The company's stock had a trading volume of 11,578,657 shares, compared to its average volume of 12,163,516. The stock has a fifty day moving average of $58.36 and a 200 day moving average of $56.13. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The firm has a market capitalization of $120.08 billion, a P/E ratio of -13.39, a PEG ratio of 2.07 and a beta of 0.43.

Remove Ads

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.19%. Bristol-Myers Squibb's dividend payout ratio is -56.11%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is owned by company insiders.

Analysts Set New Price Targets

BMY has been the subject of several analyst reports. Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and raised their target price for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Cantor Fitzgerald lifted their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Citigroup upped their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, Bank of America reissued a "neutral" rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.